Article: Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity
File Download
Links for fulltext
(May Require Subscription)
(May Require Subscription)
- Publisher Website: 10.1016/j.virol.2009.07.018
- Scopus: eid_2-s2.0-70349383960
- PMID: 19683779
- Find via
Supplementary
-
Citations:
-
Appears in Collections:
| Title | Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Authors | Du, L3 Zhao, G1 2 Chan, CCS2 Sun, S1 Chen, M2 Liu, Z3 Guo, H3 He, Y3 Zhou, Y1 Zheng, BJ2 Jiang, S3 | ||||||||
| Keywords | Neutralizing antibody Protective immunity Receptor-binding domain SARS-CoV Subunit vaccines | ||||||||
| Issue Date | 2009 | ||||||||
| Publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/yviro | ||||||||
| Citation | Virology, 2009, v. 393 n. 1, p. 144-150 [How to Cite?] DOI: http://dx.doi.org/10.1016/j.virol.2009.07.018 | ||||||||
| Abstract | Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease. The potential recurrence of the disease from animal reservoirs highlights the significance of development of safe and efficient vaccines to prevent a future SARS epidemic. In this study, we expressed the recombinant receptor-binding domain (rRBD) in mammalian (293T) cells, insect (Sf9) cells, and E. coli, respectively, and compared their immunogenicity and protection against SARS-CoV infection in an established mouse model. Our results show that all rRBD proteins expressed in the above systems maintained intact conformation, being able to induce highly potent neutralizing antibody responses and complete protective immunity against SARS-CoV challenge in mice, albeit the rRBD expressed in 293T cells elicited stronger humoral immune responses with significantly higher neutralizing activity (P < 0.05) than those expressed in Sf9 and E. coli cells. These results suggest that all three rRBDs are effective in eliciting immune responses and protection against SARS-CoV and any of the above expression systems can be used for production of rRBD-based SARS subunit vaccines. Preference will be given to rRBD expressed in mammalian cells for future evaluation of the vaccine efficacy in a non-human primate model of SARS because of its ability to refold into a native conformation more readily and to induce higher level of neutralizing antibody responses than those expressed in E. coli and insect cells. © 2009 Elsevier Inc. All rights reserved. | ||||||||
| ISSN | 0042-6822 2011 Impact Factor: 3.351 2011 SCImago Journal Rankings: 0.355 | ||||||||
| DOI | http://dx.doi.org/10.1016/j.virol.2009.07.018 | ||||||||
| ISI Accession Number ID | WOS:000270453600018
Funding Information: This study was supported by the National Institutes of Health (NIH) of the United States (R01 AI68002), by the Research Fund for the Control of Infectious Diseases, the Health, Welfare and Food Bureau of the Hong Kong SAR Government, and by the National 973 Basic Research Program of China (2005CB523001). | ||||||||
| PubMed Central ID | PMC2753736 | ||||||||
| References | References in Scopus |
| dc.contributor.author | Du, L | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| dc.contributor.author | Zhao, G | ||||||||
| dc.contributor.author | Chan, CCS | ||||||||
| dc.contributor.author | Sun, S | ||||||||
| dc.contributor.author | Chen, M | ||||||||
| dc.contributor.author | Liu, Z | ||||||||
| dc.contributor.author | Guo, H | ||||||||
| dc.contributor.author | He, Y | ||||||||
| dc.contributor.author | Zhou, Y | ||||||||
| dc.contributor.author | Zheng, BJ | ||||||||
| dc.contributor.author | Jiang, S | ||||||||
| dc.date.accessioned | 2010-10-31T11:13:26Z | ||||||||
| dc.date.available | 2010-10-31T11:13:26Z | ||||||||
| dc.date.issued | 2009 | ||||||||
| dc.description.abstract | Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease. The potential recurrence of the disease from animal reservoirs highlights the significance of development of safe and efficient vaccines to prevent a future SARS epidemic. In this study, we expressed the recombinant receptor-binding domain (rRBD) in mammalian (293T) cells, insect (Sf9) cells, and E. coli, respectively, and compared their immunogenicity and protection against SARS-CoV infection in an established mouse model. Our results show that all rRBD proteins expressed in the above systems maintained intact conformation, being able to induce highly potent neutralizing antibody responses and complete protective immunity against SARS-CoV challenge in mice, albeit the rRBD expressed in 293T cells elicited stronger humoral immune responses with significantly higher neutralizing activity (P < 0.05) than those expressed in Sf9 and E. coli cells. These results suggest that all three rRBDs are effective in eliciting immune responses and protection against SARS-CoV and any of the above expression systems can be used for production of rRBD-based SARS subunit vaccines. Preference will be given to rRBD expressed in mammalian cells for future evaluation of the vaccine efficacy in a non-human primate model of SARS because of its ability to refold into a native conformation more readily and to induce higher level of neutralizing antibody responses than those expressed in E. coli and insect cells. © 2009 Elsevier Inc. All rights reserved. | ||||||||
| dc.description.nature | link_to_OA_fulltext | ||||||||
| dc.identifier.citation | Virology, 2009, v. 393 n. 1, p. 144-150 [How to Cite?] DOI: http://dx.doi.org/10.1016/j.virol.2009.07.018 | ||||||||
| dc.identifier.citeulike | 5475713 | ||||||||
| dc.identifier.doi | http://dx.doi.org/10.1016/j.virol.2009.07.018 | ||||||||
| dc.identifier.epage | 150 | ||||||||
| dc.identifier.hkuros | 175097 | ||||||||
| dc.identifier.isi | WOS:000270453600018
Funding Information: This study was supported by the National Institutes of Health (NIH) of the United States (R01 AI68002), by the Research Fund for the Control of Infectious Diseases, the Health, Welfare and Food Bureau of the Hong Kong SAR Government, and by the National 973 Basic Research Program of China (2005CB523001). | ||||||||
| dc.identifier.issn | 0042-6822 2011 Impact Factor: 3.351 2011 SCImago Journal Rankings: 0.355 | ||||||||
| dc.identifier.issue | 1 | ||||||||
| dc.identifier.openurl | | ||||||||
| dc.identifier.pmcid | PMC2753736 | ||||||||
| dc.identifier.pmid | 19683779 | ||||||||
| dc.identifier.scopus | eid_2-s2.0-70349383960 | ||||||||
| dc.identifier.spage | 144 | ||||||||
| dc.identifier.uri | http://hdl.handle.net/10722/125136 | ||||||||
| dc.identifier.volume | 393 | ||||||||
| dc.language | eng | ||||||||
| dc.publisher | Academic Press. The Journal's web site is located at http://www.elsevier.com/locate/yviro | ||||||||
| dc.publisher.place | United States | ||||||||
| dc.relation.ispartof | Virology | ||||||||
| dc.relation.references | References in Scopus | ||||||||
| dc.subject.mesh | Antibodies, Viral - blood | ||||||||
| dc.subject.mesh | Membrane Glycoproteins - genetics - immunology | ||||||||
| dc.subject.mesh | SARS Virus - genetics - immunology | ||||||||
| dc.subject.mesh | Severe Acute Respiratory Syndrome - immunology - prevention and control | ||||||||
| dc.subject.mesh | Viral Envelope Proteins - genetics - immunology | ||||||||
| dc.subject | Neutralizing antibody | ||||||||
| dc.subject | Protective immunity | ||||||||
| dc.subject | Receptor-binding domain | ||||||||
| dc.subject | SARS-CoV | ||||||||
| dc.subject | Subunit vaccines | ||||||||
| dc.title | Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity | ||||||||
| dc.type | Article |
Author Affiliations
- Institute of Microbiology Chinese Academy of Sciences
- The University of Hong Kong
- New York Blood Center